A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

Exclusion Criteria

• •Is currently enrolled in or is planning to enroll in a formal weight-loss program
• •Is unwilling or unable to participate in a lifestyle intervention program as part of the study
• •Has been treated (within the 2 months prior to study start), is currently treated, or is expected to require or undergo treatment with any of the following excluded medications: \*prescription or over the counter antiobesity agents (within the 6 months prior to study start); \*psychotropic/neurological agents (i.e., antipsychotic, antiepileptic, antidepressant, or antianxiety agents, or mood stabilizers); \*steroids that are known to result in high systemic absorption; \*calcitonin; \*ketoconazole; \*antidiabetic medications
• •Has had liposuction, abdominoplasty, or a similar procedure within 1 year before study start or is planning to have such a procedure during the study
• •Has received any investigational drug within 1 month (or 5 half-lives of investigational drug, whichever is greater) before study start
• •Has previously used pramlintide either by prescription or as part of a clinical study
• •Has used sibutramine or phentermine (either by prescription or as part of a clinical study) within 2 years before study start
• •Has donated blood within 2 months before study start, or is planning to donate blood during the study